Adam R. Craig - Jun 30, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
President and CEO, Director
Signature
Adam R. Craig
Stock symbol
CTIC
Transactions as of
Jun 30, 2022
Transactions value $
-$361,509
Form type
4
Date filed
7/6/2022, 05:19 PM
Previous filing
Jun 3, 2022
Next filing
Aug 16, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Award $13.1K +6.18K +37.07% $2.12* 22.9K Jun 30, 2022 Direct F1
transaction CTIC common stock Options Exercise $22.7K +27K +118.11% $0.84* 49.9K Jul 1, 2022 Direct
transaction CTIC common stock Sale -$162K -27K -54.15% $6.00 22.9K Jul 1, 2022 Direct F2
transaction CTIC common stock Options Exercise $22.7K +27K +118.11% $0.84* 49.9K Jul 5, 2022 Direct
transaction CTIC common stock Sale -$162K -27K -54.15% $6.00 22.9K Jul 5, 2022 Direct F2
transaction CTIC common stock Options Exercise $15.3K +18.2K +79.71% $0.84* 41.1K Jul 6, 2022 Direct
transaction CTIC common stock Sale -$111K -18.2K -44.36% $6.11 22.9K Jul 6, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27K -2.2% $0.00 1.2M Jul 1, 2022 Common Stock 27K $0.84 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27K -2.25% $0.00 1.17M Jul 5, 2022 Common Stock 27K $0.84 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -18.2K -1.55% $0.00 1.16M Jul 6, 2022 Common Stock 18.2K $0.84 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
F2 This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
F3 One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.